Display options
Cite
Teschke R, Eickhoff A, Schulze J. Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?. J Clin Transl Hepatol. 2013;1(1):59-74doi: 10.14218/JCTH.2013.D002X.
Teschke, R., Eickhoff, A., & Schulze, J. (2013). Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?. Journal of clinical and translational hepatology, 1(1), 59-74. https://doi.org/10.14218/JCTH.2013.D002X
Teschke, Rolf, et al. "Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?." Journal of clinical and translational hepatology vol. 1,1 (2013): 59-74. doi: https://doi.org/10.14218/JCTH.2013.D002X
Teschke R, Eickhoff A, Schulze J. Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?. J Clin Transl Hepatol. 2013 Sep;1(1):59-74. doi: 10.14218/JCTH.2013.D002X. Epub 2013 Sep 15. PMID: 26357608; PMCID: PMC4521275.
Copy Download .nbib Format: NLM
Share it on

J Clin Transl Hepatol. 2013 Sep;1(1):59-74. doi: 10.14218/JCTH.2013.D002X. Epub 2013 Sep 15.

Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?.

Journal of clinical and translational hepatology

Rolf Teschke, Axel Eickhoff, Johannes Schulze

Affiliations

  1. Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/ Main, Germany.
  2. Institute of Industrial, Environmental and Social Medicine, Medical Faculty, Goethe University Frankfurt/Main, Germany.

PMID: 26357608 PMCID: PMC4521275 DOI: 10.14218/JCTH.2013.D002X

Abstract

Drug-induced liver injury (DILI) and herb-induced liver injury (HILI) are typical diseases of clinical and translational hepatology. Their diagnosis is complex and requires an experienced clinician to translate basic science into clinical judgment and identify a valid causality algorithm. To prospectively assess causality starting on the day DILI or HILI is suspected, the best approach for physicians is to use the Council for International Organizations of Medical Sciences (CIOMS) scale in its original or preferably its updated version. The CIOMS scale is validated, liver-specific, structured, and quantitative, providing final causality grades based on scores of specific items for individual patients. These items include latency period, decline in liver values after treatment cessation, risk factors, co-medication, alternative diagnoses, hepatotoxicity track record of the suspected product, and unintentional re-exposure. Provided causality is established as probable or highly probable, data of the CIOMS scale with all individual items, a short clinical report, and complete raw data should be transmitted to the regulatory agencies, manufacturers, expert panels, and possibly to the scientific community for further refinement of the causality evaluation in a setting of retrospective expert opinion. Good-quality case data combined with thorough CIOMS-based assessment as a standardized approach should avert subsequent necessity for other complex causality assessment methods that may have inter-rater problems because of poor-quality data. In the future, the CIOMS scale will continue to be the preferred tool to assess causality of DILI and HILI cases and should be used consistently, both prospectively by physicians, and retrospectively for subsequent expert opinion if needed. For comparability and international harmonization, all parties assessing causality in DILI and HILI cases should attempt this standardized approach using the updated CIOMS scale.

Keywords: Causality assessment; Drug hepatotoxicity; Drug-induced liver injury; Herb-induced liver injury; Herbal hepatotoxicity

References

  1. Gastroenterology. 2011 Nov;141(5):1665-72.e1-9 - PubMed
  2. Regul Toxicol Pharmacol. 2011 Feb;59(1):1-7 - PubMed
  3. Ann Hepatol. 2012 Jul-Aug;11(4):544-9 - PubMed
  4. J Hepatol. 2000 Dec;33(6):1003-5 - PubMed
  5. Phytomedicine. 2009 Jan;16(1):72-84 - PubMed
  6. Aliment Pharmacol Ther. 2008 May;27(9):780-9 - PubMed
  7. Menopause. 2009 Sep-Oct;16(5):956-65 - PubMed
  8. Regul Toxicol Pharmacol. 2012 Jun;63(1):1-9 - PubMed
  9. Ann Hepatol. 2009 Jul-Sep;8(3):258-66 - PubMed
  10. J Hepatol. 2000 Dec;33(6):949-52 - PubMed
  11. Clin Pharmacol Ther. 2011 Jun;89(6):806-15 - PubMed
  12. Clin Toxicol (Phila). 2011 Jan;49(1):34-9 - PubMed
  13. Hepatology. 2010 Jun;51(6):2117-26 - PubMed
  14. Aliment Pharmacol Ther. 2013 Jan;37(1):3-17 - PubMed
  15. J Clin Epidemiol. 1993 Nov;46(11):1331-6 - PubMed
  16. Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):843-60 - PubMed
  17. J Clin Pharm Ther. 2003 Apr;28(2):137-43 - PubMed
  18. Gastroenterol Clin Biol. 1987 Aug-Sep;11(8-9):581-5 - PubMed
  19. BMJ. 1999 Dec 11;319(7224):1541 - PubMed
  20. Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1093-8 - PubMed
  21. Eur J Gastroenterol Hepatol. 2012 Mar;24(3):270-80 - PubMed
  22. Hepatol Res. 2003 Nov;27(3):192-195 - PubMed
  23. World J Hepatol. 2013 Jul 27;5(7):353-63 - PubMed
  24. J Clin Pharm Ther. 2010 Oct;35(5):545-63 - PubMed
  25. Drug Saf. 2008;31(1):21-37 - PubMed
  26. Pharmacoepidemiol Drug Saf. 2011 Oct;20(10 ):1080-7 - PubMed
  27. Gut. 1999 May;44(5):731-5 - PubMed
  28. Hepatology. 2001 Jan;33(1):308-10 - PubMed
  29. Clin Pharmacol Ther. 1977 Mar;21(3):247-54 - PubMed
  30. J Hepatol. 1988 Aug;7(1):132-6 - PubMed
  31. Gastroenterology. 2008 Dec;135(6):1924-34, 1934.e1-4 - PubMed
  32. Clin Pharmacol Ther. 1981 Aug;30(2):239-45 - PubMed
  33. Drug Saf. 2009;32(1):55-68 - PubMed
  34. World J Gastroenterol. 2008 Nov 28;14 (44):6774-85 - PubMed
  35. Ann Hepatol. 2012 Jul-Aug;11(4):564-9 - PubMed
  36. Ann Hepatol. 2012 Jul-Aug;11(4):500-12 - PubMed
  37. Gastroenterology. 2005 Aug;129(2):512-21 - PubMed
  38. Regul Toxicol Pharmacol. 2011 Dec;61(3):282-91 - PubMed
  39. Hepatology. 2001 Jan;33(1):123-30 - PubMed
  40. Rev Esp Enferm Dig. 2008 Nov;100(11):688-95 - PubMed
  41. World J Gastroenterol. 2013 May 21;19(19):2864-82 - PubMed
  42. Therapie. 1985 Mar-Apr;40(2):111-8 - PubMed
  43. Expert Opin Drug Saf. 2013 May;12 (3):339-66 - PubMed
  44. J Hepatol. 1990 Sep;11(2):272-6 - PubMed
  45. Am J Gastroenterol. 2010 Jul;105(7):1561-6 - PubMed
  46. Hepatol Res. 2004 Nov;30(3):148-154 - PubMed
  47. Regul Toxicol Pharmacol. 2012 Nov;64(2):342; author reply 343-4 - PubMed
  48. Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):567-82 - PubMed
  49. Ann Hepatol. 2013 Jan-Feb;12 (1):11-21 - PubMed
  50. Clin Gastroenterol Hepatol. 2010 May;8(5):463-70 - PubMed
  51. Br J Clin Pharmacol. 2008 Dec;66(6):758-66 - PubMed
  52. J Hepatol. 2011 Sep;55(3):683-91 - PubMed
  53. Drug Saf. 2012 Dec 1;35(12 ):1091-7 - PubMed
  54. Hepatology. 1997 Sep;26(3):664-9 - PubMed
  55. Hepatology. 2008 Oct;48(4):1175-83 - PubMed
  56. J Clin Epidemiol. 1993 Nov;46(11):1323-30 - PubMed

Publication Types